Multicyclic Compounds for PAK Inhibition in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective drug-like compounds that can specifically target and inhibit p21-activated kinases (PAK), which are involved in cancer progression, particularly in lymphoma and other PAK-mediated disorders.
Innovation Solution
Development of multicyclic compounds that modulate PAK activity by binding to and destabilizing PAKs, thereby inhibiting downstream proteins like Akt, ERK1/2, and β-catenin, offering a therapeutic approach for treating cancer and PAK-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cancer treatments are used, then general cancer therapy is provided, but specific targeting of PAK kinases is not achieved
Solution Approach 1:
The compound is designed with specific functional groups and structural features that selectively interact with PAK kinase binding pockets, providing localized specificity to the target protein family while maintaining overall molecular stability and drug-like properties
Solution Approach 2:
The multicyclic compound structure with specific ring systems, substituent patterns, and molecular parameters is optimized to match the binding characteristics of PAK kinases, changing the physical-chemical parameters to achieve selective inhibition of this protein family
2Measurement precision
If multicyclic compounds are developed to target PAKs, then specific PAK inhibition is achieved, but the complexity of the compound structure increases
Solution Approach 1:
The multicyclic compound is constructed from multiple cyclic units (aromatic rings, heterocyclic rings) that are segmented and connected through linker groups, allowing each ring to contribute specific binding interactions while maintaining overall structural organization
Solution Approach 2:
The compound features nested or fused ring systems where smaller cyclic structures are incorporated within or adjacent to larger ring systems, creating a compact multicyclic architecture that maximizes binding surface area while controlling molecular complexity
3Reliability
If compounds bind to and destabilize PAKs, then downstream signaling is inhibited, but the mechanism of action becomes more complex
Solution Approach 1:
The compound binds to PAK kinases in advance to prevent their activation or stabilize inactive conformations, thereby preemptively blocking downstream signaling pathways before they can be activated by upstream signals
Solution Approach 2:
The multicyclic compound acts as an intermediary molecule that bridges the inhibition need between upstream signaling regulation and downstream protein activity, mediating the blocking effect through direct PAK binding and conformational stabilization
Data Source
AI summary
The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).